AMGEN INC.

ISIN: US0311621009 WKN: 031162100 Asset Class: Stock

340.00 Company 2024/05/06 18:15:20 320.00 **Price** 300.00 298.40 USD 280.00 Difference -4.14%(-12.90) 260.00 240.00 **Contact Details** 220.00 AMGEN INC. Tel: +1-805-447-1000 Fax: +1-805-447-1010 - -200.00 One Amgen Center Drive 06.2023 08.2023 10.2023 12.2023 02.2024 04.2024 Web: http://www.amgen.com 91320-1799 Thousand Oaks E-mail: -

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	30,332,000,000		22,186,000,000		19,385,000,000	
Common stock capital		33,070,000,000		32,514,000,000		32,096,000,000
Fixed assets	66,822,000,000		42,935,000,000		41,780,000,000	
Equity capital of a company		6,232,000,000		3,661,000,000		6,700,000,000
Cash and cash equivalents	10,944,000,000		7,629,000,000		7,989,000,000	
Accrued liabilities		4,680,000,000		5,757,000,000		6,594,000,000
Other assets	-		-		-	
Current liabilities		18,392,000,000		15,687,000,000		12,184,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		72,530,000,000		45,773,000,000		42,281,000,000
Different income		-		-		-
Other liabilities		1,635,000,000		2,123,000,000		1,940,000,000
Total assets	97,154,000,000	97,154,000,000	65,121,000,000	65,121,000,000	61,165,000,000	61,165,000,000

Ba	lan	ce	n	ote	S
Da	an	CC		ole	\sim

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	26,700	25,200	24,200
Equity ratio	6.41%	5.62%	10.95%
Debt-equity ratio	1,458.95%	1,678.78%	812.91%

Others

	2023	2022	2021
Tax Expense Rate	14.49%	10.81%	12.06%

AMGEN INC.

ISIN:	US0311621009	WKN:	031162100	Asset Class:	Stock

Income statement				
	2023	2022	2021	
Turnover	28,010,000,000	26,092,000,000	25,987,000,000	
Net income	6,717,000,000	6,552,000,000	5,893,000,000	
EBIT	10,081,444,000	8,231,424,000	7,443,884,000	
Operating income before taxes	7,855,000,000	7,346,000,000	6,701,000,000	
Cash Flow	8,471,000,000	9,721,000,000	9,261,000,000	
Net interest income	-2,962,000,000	-1,486,000,000	-1,286,000,000	
Research and development expenses	4,755,000,000	4,434,000,000	4,819,000,000	
Income taxes	1,138,000,000	794,000,000	808,000,000	
Result from investments in subsidaries, associates and other	-	-	0	
Revenues per employee	977,727	964,990	1,000,822	

Board of Directors

Members of Management Board

Brian Druker	Member of Board of Directors
Michael Drake	Member of Board of Directors
Omar Ishrak	Member of Board of Directors
Robert Williams	Member of Board of Directors
Ronald Sugar	Member of Board of Directors
Tyler Jacks	Member of Board of Directors
Wanda Austin	Member of Board of Directors
Amy Miles	Member of Board of Directors
Charles Holley	Member of Board of Directors
Ellen Kullman	Member of Board of Directors
Greg Garland	Member of Board of Directors
Robert Eckert	Member of Board of Directors
Robert A. Bradway	Chairman of Managing Board
David M. Reese	Member of Executive Committee
Jackie Elbonne	Member of Executive Committee
James Bradner	Member of Executive Committee
Jonathan Graham	Member of Executive Committee
Mike Zahigan	Member of Executive Committee
Murdo Gordon	Member of Executive Committee
Paul Burton	Member of Executive Committee
Peter Griffith	Member of Executive Committee